Boehringer In­gel­heim touts pre­ven­tion re­sults in rarest form of pso­ri­a­sis

Boehringer In­gel­heim un­corked some pos­i­tive re­sults sug­gest­ing that Spe­vi­go can help pre­vent flare-ups in pa­tients with a se­vere form of pso­ri­a­sis, months af­ter the drug was ap­proved to treat ex­ist­ing flares.

Spe­vi­go, an IL-36R an­ti­body al­so known as spesolimab, met its pri­ma­ry and a key sec­ondary end­point in the Phase IIb EFF­ISAY­IL 2 tri­al in pa­tients with gen­er­al­ized pus­tu­lar pso­ri­a­sis (GPP), Boehringer an­nounced on Mon­day. While the com­pa­ny is keep­ing the hard num­bers un­der wraps un­til lat­er this year, it said in a news re­lease that it an­tic­i­pates shar­ing the re­sults with reg­u­la­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.